Previous 10 | Next 10 |
home / stock / ipcif / ipcif news
JPMorgan Chase & Co. (JPM) is expected to report $3.89 for Q3 2023 Unity Bancorp Inc. (UNTY) is expected to report $0.89 for Q3 2023 Wells Fargo & Company (WFC) is expected to report $1.25 for Q3 2023 Intellipharmaceutics International Inc (IPCIF) is expected to report for Q1 ...
Intellipharmaceutics International Inc (IPCIF) is expected to report for Q1 2024
2023-07-17 10:55:47 ET Intellipharmaceutics International press release ( OTC:IPCIF ): Q2 GAAP EPS of $0.00. Revenue of $480.21M. For further details see: Intellipharmaceutics International GAAP EPS of $0.00, revenue of $480.21M
TORONTO, ON / ACCESSWIRE / July 14, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release...
2023-06-06 06:24:37 ET Intellipharmaceutics International press release ( OTC:IPCIF ): FY GAAP EPS of -$0.09. Revenue of $0.06M. For First Quarter 2023: The Company recorded GAAP EPS of -$0.01/common share. The company recorded revenues of $0.33M for the three mont...
Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results Canada NewsWire TORONTO , June 6, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical c...
Intellipharmaceutics Announces Cease Trade Order Canada NewsWire TORONTO , March 7, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the...
Intellipharmaceutics Provides Update on Management Cease Trade Order Application and Anticipates Cease Trade Order Canada NewsWire TORONTO , Feb. 7, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) (" Intellipharmaceutics " or t...
Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form and its Management Cease Trade Order Application Canada NewsWire TORONTO , Feb. 6, 2023 /CNW/ - Intellipharmaceutics International Inc. (OT...
TORONTO, ON / ACCESSWIRE / October 14, 2022 / - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-r...
News, Short Squeeze, Breakout and More Instantly...
Intellipharmaceutics International Inc Company Name:
IPCIF Stock Symbol:
OTCMKTS Market:
Intellipharmaceutics International Inc Website:
TORONTO, ON / ACCESSWIRE / June 14, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI.H) (" Intellipharmaceutics " or the " Company "), announced today that its common stock, currently traded on the OTCQB market, is expected to be downgraded to the OTC Expert Market on J...
MJ Holdings Inc (MJNE) is expected to report for Q1 2024 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.17 for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Luna Innovations Incorporated (LUNA) is expected to report $-0.01 for Q1 2024 Cano Health...
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rel...